Bronchiectasis

Tuberculosis and Respiratory Diseases

Volumn 73, Issue 5, 2012, Pages 249-257

  Kim, Changhwan ^a   Kim, Dong Gyu ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Bronchiectasis; Etiology; Immunologic deficiency syndromes; Therapeutics

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CORTICOSTEROID; ERDOSTEINE; GENTAMICIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MACROLIDE; MANNITOL; MUCOLYTIC AGENT; PNEUMOCOCCUS VACCINE; SODIUM CHLORIDE; TOBRAMYCIN;

AGAMMAGLOBULINEMIA; ASTHMA; BREATHING EXERCISE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASS SWITCH RECOMBINATION DEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; CYSTIC FIBROSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW;

EID: 84871505228     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2012.73.5.249     Document Type: Review

References (62)

1. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010;86:493-501.
2. Barker AF, Bardana EJ Jr. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988;137:969-78. (Pubitemid 18099320)
3. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010;138:944-9.
4. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104:981-5.
5. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-45. (Pubitemid 41140504)
6. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008;14:595-9.
7. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012;67:1006-13.
8. Li AM, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005;26:8-14. (Pubitemid 40945925)
9. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007;101:1163-70. (Pubitemid 46667677)
10. Zoumot Z, Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis 2010;23:165-70.
11. O'Donnell AE. Bronchiectasis. Chest 2008;134:815-23.
12. Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr 2011;170:693-702.
13. Stead A, Douglas JG, Broadfoot CJ, Kaminski ER, Herriot R. Humoral immunity and bronchiectasis. Clin Exp Immunol 2002;130:325-30. (Pubitemid 35286222)
14. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009;124:1161-78.
15. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999;93:190-7.
16. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(5 Suppl 1):S1-63.
17. King PT, Hutchinson P, Holmes PW, Freezer NJ, Bennett-Wood V, Robins-Browne R, et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol 2006;144:440-6. (Pubitemid 43799927)
18. De Gracia J, Rodrigo MJ, Morell F, Vendrell M, Miravitlles M, Cruz MJ, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996;153:650-5. (Pubitemid 26051343)
19. Kim CH, Kim DG, Park SH, Choi JH, Lee CY, Hwang YI, et al. Incidence of immunoglobulin G subclass deficiencies in patients with bronchiectasis and the clinical characteristics of patients with immunoglobulin G subclass deficiency and bronchiectasis. Tuberc Respir Dis 2009;66:295-9.
20. Feldman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med 2011;32:535-46.
21. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4 Pt 1):1277-84.
22. Sorensen RU, Leiva LE, Javier FC 3rd, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998;102:215-21. (Pubitemid 28406908)
23. Jeurissen A, Moens L, Raes M, Wuyts G, Willebrords L, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens. Clin Chem 2007;53:505-10. (Pubitemid 46447948)
24. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol 2010;134:198-205.
25. Stafler P, Carr SB. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed 2010;95:73-82.
26. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65 Suppl 1:i1-58.
27. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53.
28. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999;92:34-48. (Pubitemid 29315984)
29. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011;164 Suppl 2:2-5.
30. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol 2010;159:344-50.
31. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001;(4):CD002155.
32. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001;(4):CD002163.
33. Saito Y, Azuma A, Morimoto T, Fujita K, Abe S, Motegi T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008;47:585-91. (Pubitemid 351936245)
34. Li XL, Cai SX, Zhao HJ, Dong LM, Shen XB, Liu LY, et al. Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis. Nan Fang Yi Ke Da Xue Xue Bao 2010;30:1072-4.
35. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60:239-43. (Pubitemid 40380285)
36. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006;100:1623-32. (Pubitemid 44089352)
37. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-7. (Pubitemid 28449432)
38. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009;(1):CD000996.
39. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;(5):CD005535.
40. Martínez-Garda MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141:461-8.
41. Cole PJ. Inflammation. A two-edged sword: the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15. (Pubitemid 16017382)
42. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007;(2):CD001392.
43. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-6. (Pubitemid 46224309)
44. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-9.
45. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;2171-6.
46. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138:1202-12.
47. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009;33:171-81.
48. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;174:928-34. (Pubitemid 44564794)
49. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011;81:75-87.
50. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 2007;67:965-74. (Pubitemid 46744473)
51. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(3):CD001287.
52. Crisafulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther 2007;29:2001-9. (Pubitemid 350212798)
53. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8. (Pubitemid 29275053)
54. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006;(2):CD002996.
55. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 2012;17:927-32.
56. King PT, Daviskas E. Management of bronchiectasis. Breathe 2010;6:353-60.
57. Murray MP, Pentland JL, Hill AT. A randomised cross-over trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086-92.
58. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst Rev 2000;(2):CD000045.
59. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007;(3):CD006218.
60. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009;(2):CD006316.
61. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008;26:4284-9.
62. Sørensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC 3rd, Sacerdote DM, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998;17:685-91. (Pubitemid 28388156)